×
About 10,498 results

ALLMedicine™ Nasopharyngeal Carcinoma Center

Research & Reviews  3,983 results

RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107765
BMC Cancer; Lin C, Li M et. al.

May 16th, 2022 - Accumulated evidence suggests that RING finger proteins (RNFs) are involved in the carcinogenesis of cancers. However, RNF38, a member of the RNF protein family, has not been studied in nasopharyngeal carcinoma (NPC). RNF38 expression was analyzed...

Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value a...
https://doi.org/10.1016/j.radonc.2022.05.004
Radiotherapy and Oncology : Journal of the European Socie... Yi-Liang Shen E, Hung TM et. al.

May 15th, 2022 - To determine the clinical impact of integrating Epstein-Barr virus (EBV) DNA and lymph node-to-primary tumor ratio (NTR) of positron emission tomography (PET) standardized uptake value (SUV) in predicting distant metastasis, such as distant metast...

Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasop...
https://doi.org/10.1016/j.ijrobp.2022.04.049
International Journal of Radiation Oncology, Biology, Phy... Liu X, Guo L et. al.

May 14th, 2022 - We previously demonstrated that real-time monitoring of plasma Epstein-Barr virus DNA (EBV DNA) during chemoradiotherapy defined four distinct phenotypic clusters of nasopharyngeal carcinoma. In particular, the treatment-resistant group, defined a...

Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107145
Molecular Medicine (Cambridge, Mass.); Zhou Z, Li P et. al.

May 14th, 2022 - The aim of this study was to draw a comprehensive mutational landscape of nasopharyngeal carcinoma (NPC) tumors and identify the prognostic factors for distant metastasis-free survival (DMFS). A total of forty primary nonkeratinizing NPC patients ...

Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066117
International Journal of Biological Sciences; Wang H, Wang W et. al.

May 12th, 2022 - Nasopharyngeal carcinoma (NPC) is a kind of malignant tumor with ethnic and geographical distribution characteristics. However, the molecular mechanisms of NPC are still unclear. Long non encoding RNAs (lncRNAs) are becoming important regulators i...

see more →

Guidelines  7 results

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage ...
https://doi.org/10.1200/JCO.20.03237
Journal of Clinical Oncology : Official Journal of the Am... Chen YP, Ismaila N et. al.

Jan 7th, 2021 - The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC). The Chinese ...

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, trea...
https://doi.org/10.1016/j.annonc.2020.12.007
Annals of Oncology : Official Journal of the European Soc... Bossi P, Chan AT et. al.

Dec 29th, 2020 - Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2020|Bossi P,Chan AT,Licitra L,Trama A,Orlandi E,|diagnosis,epidemiology,therapy,diagnosis,epidemiology,therapy,

International Guideline on Dose Prioritization and Acceptance Criteria in Radiation The...
https://doi.org/10.1016/j.ijrobp.2019.06.2540
International Journal of Radiation Oncology, Biology, Phy... Lee AW, Ng WT et. al.

Jul 6th, 2019 - The treatment of nasopharyngeal carcinoma requires high radiation doses. The balance of the risks of local recurrence owing to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. W...

SEOM clinical guideline in nasopharynx cancer (2017).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785612
Clinical & Translational Oncology : Official Publication ... Pastor M, Lopez Pousa A et. al.

Nov 4th, 2017 - Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiation therapy is an essential component of curative-intent of non-disseminated ...

Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873914
The Journal of Laryngology and Otology; Simo R, Robinson M et. al.

Nov 15th, 2016 - This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Although much commoner in the eastern hemisphere, with an age-standardised incidence rate of 0.39 per 100 000 po...

see more →

Clinicaltrials.gov  175 results

NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer
https://clinicaltrials.gov/ct2/show/NCT03734809

May 12th, 2022 - Nasopharyngeal cancer (NPC) is a predominantly Asian disease, with approximately 80% of the world's 86000 cases occurring in Asian countries (12). With advances in radiation technology such as intensity modulation radiotherapy (IMRT), local and no...

Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
https://clinicaltrials.gov/ct2/show/NCT05350891

May 10th, 2022 - A Prospective, Single-arm, Multicenter Clinical Study of Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent Nasopharyngeal Carcinoma

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03700476

May 9th, 2022 - This trial plans to enroll patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Patients will be randomized in a 1:1 ratio to receive 3 cycles of induction chemotherapy with gemcit...

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
https://clinicaltrials.gov/ct2/show/NCT05304468

May 6th, 2022 - To explore the 2 year PFS of patients with stageII-III nasopharyngeal carcinoma treated with induction chemotherapy followed by reduced-dose radiotherapy and cisplatin versus standard dose radiotherapy plus cisplatin concurrent chemotherapy. The e...

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
https://clinicaltrials.gov/ct2/show/NCT05201859

May 6th, 2022 - Currently, although NCCN (National Comprehensive Cancer Network) guidelines recommend induction chemotherapy combined with concurrent chemoradiotherapy as IIA level-evidenced treatment for nasopharyngeal carcinoma (NPC), there are still about 20-3...

see more →

News  34 results

FDA Rejects More China Drugs; Clue to Uterine Ca Disparity; Cancer-Vax Controversy
https://www.medpagetoday.com/hematologyoncology/othercancers/98587

May 6th, 2022 - China-based Hutchmed announced receipt of a complete response letter from the FDA, stating that the agency cannot approve the tyrosine kinase inhibitor surufatinib for advanced neuroendocrine tumors without support from a multiregional clinical tr...

FDA Issues Complete Response Letter to Toripalimab for Nasopharyngeal Carcinoma
https://www.onclive.com/view/fda-issues-complete-response-letter-to-toripalimab-for-nasopharyngeal-carcinoma

May 2nd, 2022 - The FDA has issued a complete response letter (CRL) to the biologics license application (BLA) seeking the approval of toripalimab for use in combination with gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent...

FDA Issues Complete Response Letter for Nasopharyngeal Carcinoma Drug Toripalimab
https://www.medscape.com/viewarticle/973242

May 2nd, 2022 - Drug manufacturers Coherus and Junshi Biosciences announced today that the US Food and Drug Administration (FDA) has issued a complete response letter for the biologics license application (BLA) for toripalimab for the treatment of advanced recurr...

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

PD-1 Inhibition Shows 'Clear' Benefit in Nasopharyngeal Carcinoma
https://www.medpagetoday.com/hematologyoncology/othercancers/98310

Apr 20th, 2022 - Adding the PD-1 inhibitor tislelizumab to chemotherapy led to a progression-free survival (PFS) improvement for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to updated results from a phase III randomized trial. O...

see more →